EU/3/15/1531: Orphan designation for the treatment of Rett syndrome
Sarizotan hydrochloride
Table of contents
Overview
On 28 July 2015, orphan designation (EU/3/15/1531) was granted by the European Commission to Newron Pharmaceuticals SpA, Italy, for sarizotan hydrochloride for the treatment of Rett syndrome.
Key facts
Active substance |
Sarizotan hydrochloride
|
Intended use |
Treatment of Rett syndrome
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/15/1531
|
Date of designation |
28/07/2015
|
Sponsor |
Newron Pharmaceuticals SpA
Via Lodovico Aristo 20091 Bresso Milan Italy Tel. +39 0261034622 Fax +39 0261034654 or +39 0261034655 E-mail: info@newron.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: